Mitochondria and Schizophrenia: Effects of Antipsychotic Drugs

Chang Gung Memorial Hospital77 enrolled

Overview

The investigators will investigate 1. the relationships between oxidative stress-, apoptosis-related markers, mitochondria DNA copy numbers and the clinical psychopathology of schizophrenia, including severity of positive and negative symptoms, obesity and metabolic syndrome. 2. the relationships between aberrant mitochondria genes (single nucleotide polymorphism of D-loop region-related genes and haplogroup N9a), DISC1 gene polymorphism, and clinical phenotypes in Taiwanese populations. 3. whether these biological markers could be as clinical markers in schizophrenia for a long-term follow-up study.

In past study, we had shown that there were significant differences in serum Lpo (lipid peroxidation) and Thiol levels between patients with schizophrenia and healthy controls. For patients taking risperidone, there were significant decreases in serum Thiol levels. In addition, there were also significant differences in age of onset of PPAR gamma coactivator 1α (PGC-1α) polymorphism for schizophrenia patients. Therefore, we want to know the relationships between oxidative stress-, apoptosis-related markers, mitochondria DNA copy numbers and the clinical psychopathology of schizophrenia, including severity of positive and negative symptoms, obesity and metabolic syndrome. In past study, we also found that there were significant differences in 10 SNPs located in the D-loop region-related genes between patients and healthy controls. Three SNPs could be found in Mitomap data, but another seven SNPs not been found in the Mitomap and they could be more confirmed. In addition, Tanaka et al. found that haplogroup N9a was related to diabetes and metabolic syndrome in Asia. Therefore, we were interested to clarify the relationships between above related mitochondria genes and clinical phenotypes in Taiwanese populations,. In addition, we also want to see whether these biological markers could be as clinical markers in schizophrenia for a long-term follow-up study.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Schizophrenia

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Schizophrenic patients will be recruited in psychiatric inpatients and outpatients departments according to DSM-IV criteria by a semi-structured interview. The assessment will be done by two senior psychiatrists. The intra- rater and inter-rater reliability will be done before this project started. 2. The patients had the ability to complete the written inform consent. Exclusion Criteria: 1. Alcohol abuse or dependence 2. Smoking more than 1 pack per day 3. Concurrent use of mood stabilizer or beta-blocker

Locations (1)

Department of Psychiatry, Chang Gung Memorial Hospital

Kaohsiung City, Taiwan

Outcomes

Primary Outcomes

Serum oxidative stress

serum malondialdehyde (MDA) content, serum free thiols, serum glutathione, catalase, Superoxide dismutase, glutathione peroxidase, proapoptotic markers (bad and bax) and antiapoptotic markers (bcl-2 and bcl-x1), quantification of mitochondrial DNA

Time frame: 15 months

DISC1 gene polymorphism

Time frame: 15 months

Secondary Outcomes

PANSS score

Positive and Negative Syndrome Scale to reflect the severity of psychopathology

Time frame: 15 months

Obesity

obesity defined by body mass index (BMI)\>=26.4

Time frame: 15 months

Metabolic syndrome

Time frame: 15 months

Drug response

Time frame: 15 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.